Tumour burden predicts treatment resistance in patients with early unfavourable or advanced stage Hodgkin lymphoma treated with ABVD and radiotherapy

Paolo G. Gobbi, Emilio Bassi, Manuela Bergonzi, Francesco Merli, Chiara Coriani, Emilio Iannitto, Stefano Luminari, Giuseppe Polimeno, Massimo Federico

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The purpose of the work was to investigate the factors predicting early resistance to treatment in Hodgkin lymphoma. Many staging parameters, including relative tumour burden (rTB), were analysed in 246 patients with Hodgkin lymphoma in relation to early failure, that is, less than complete remission (i.e. partial response, null response or progression) or occurrence of early relapse, as clinical expressions of resistance to treatment. Patients with early unfavourable disease were 129 and were treated with four to six cycles of ABVD + involved field radiotherapy; 117 patients with advanced stage disease received six cycles of ABVD + optional irradiation to no more than two sites. The rTB was volumetrically measured through the evaluation of staging computed tomography for all the lesions except bone marrow involvement, which was quantified by calculation. The relationship with early resistance was analysed with logistic regressions. The rTB demonstrated to be the best predictor of early failure in both patient subsets, being superior to the multiparameter International Prognostic Score. The rTB showed a significant exponential relationship with the relative risk of early failure, and with inclusion of the extranodal involvement into the model, a single equation became adequate to predict resistance in both early unfavourable and advanced stage patients. The conclusions are that the rTB is the best pretreatment factor related to the risk of resistance to combined ABVD + radiotherapy and that this relationship can be mathematically expressed in an easy way. A simplified assessment of rTB is highly desirable.

Original languageEnglish
Pages (from-to)194-199
Number of pages6
JournalHematological Oncology
Volume30
Issue number4
DOIs
Publication statusPublished - Dec 2012

Fingerprint

Tumor Burden
Hodgkin Disease
Radiotherapy
Therapeutics
Logistic Models
Bone Marrow
Tomography
Recurrence

Keywords

  • Chemotherapy
  • Clinical response
  • Early relapse
  • Radiotherapy
  • Tumour burden

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Tumour burden predicts treatment resistance in patients with early unfavourable or advanced stage Hodgkin lymphoma treated with ABVD and radiotherapy. / Gobbi, Paolo G.; Bassi, Emilio; Bergonzi, Manuela; Merli, Francesco; Coriani, Chiara; Iannitto, Emilio; Luminari, Stefano; Polimeno, Giuseppe; Federico, Massimo.

In: Hematological Oncology, Vol. 30, No. 4, 12.2012, p. 194-199.

Research output: Contribution to journalArticle

Gobbi, Paolo G. ; Bassi, Emilio ; Bergonzi, Manuela ; Merli, Francesco ; Coriani, Chiara ; Iannitto, Emilio ; Luminari, Stefano ; Polimeno, Giuseppe ; Federico, Massimo. / Tumour burden predicts treatment resistance in patients with early unfavourable or advanced stage Hodgkin lymphoma treated with ABVD and radiotherapy. In: Hematological Oncology. 2012 ; Vol. 30, No. 4. pp. 194-199.
@article{95a0f467d36b46098235f84330d54c52,
title = "Tumour burden predicts treatment resistance in patients with early unfavourable or advanced stage Hodgkin lymphoma treated with ABVD and radiotherapy",
abstract = "The purpose of the work was to investigate the factors predicting early resistance to treatment in Hodgkin lymphoma. Many staging parameters, including relative tumour burden (rTB), were analysed in 246 patients with Hodgkin lymphoma in relation to early failure, that is, less than complete remission (i.e. partial response, null response or progression) or occurrence of early relapse, as clinical expressions of resistance to treatment. Patients with early unfavourable disease were 129 and were treated with four to six cycles of ABVD + involved field radiotherapy; 117 patients with advanced stage disease received six cycles of ABVD + optional irradiation to no more than two sites. The rTB was volumetrically measured through the evaluation of staging computed tomography for all the lesions except bone marrow involvement, which was quantified by calculation. The relationship with early resistance was analysed with logistic regressions. The rTB demonstrated to be the best predictor of early failure in both patient subsets, being superior to the multiparameter International Prognostic Score. The rTB showed a significant exponential relationship with the relative risk of early failure, and with inclusion of the extranodal involvement into the model, a single equation became adequate to predict resistance in both early unfavourable and advanced stage patients. The conclusions are that the rTB is the best pretreatment factor related to the risk of resistance to combined ABVD + radiotherapy and that this relationship can be mathematically expressed in an easy way. A simplified assessment of rTB is highly desirable.",
keywords = "Chemotherapy, Clinical response, Early relapse, Radiotherapy, Tumour burden",
author = "Gobbi, {Paolo G.} and Emilio Bassi and Manuela Bergonzi and Francesco Merli and Chiara Coriani and Emilio Iannitto and Stefano Luminari and Giuseppe Polimeno and Massimo Federico",
year = "2012",
month = "12",
doi = "10.1002/hon.1024",
language = "English",
volume = "30",
pages = "194--199",
journal = "Hematological Oncology",
issn = "0278-0232",
publisher = "wiley",
number = "4",

}

TY - JOUR

T1 - Tumour burden predicts treatment resistance in patients with early unfavourable or advanced stage Hodgkin lymphoma treated with ABVD and radiotherapy

AU - Gobbi, Paolo G.

AU - Bassi, Emilio

AU - Bergonzi, Manuela

AU - Merli, Francesco

AU - Coriani, Chiara

AU - Iannitto, Emilio

AU - Luminari, Stefano

AU - Polimeno, Giuseppe

AU - Federico, Massimo

PY - 2012/12

Y1 - 2012/12

N2 - The purpose of the work was to investigate the factors predicting early resistance to treatment in Hodgkin lymphoma. Many staging parameters, including relative tumour burden (rTB), were analysed in 246 patients with Hodgkin lymphoma in relation to early failure, that is, less than complete remission (i.e. partial response, null response or progression) or occurrence of early relapse, as clinical expressions of resistance to treatment. Patients with early unfavourable disease were 129 and were treated with four to six cycles of ABVD + involved field radiotherapy; 117 patients with advanced stage disease received six cycles of ABVD + optional irradiation to no more than two sites. The rTB was volumetrically measured through the evaluation of staging computed tomography for all the lesions except bone marrow involvement, which was quantified by calculation. The relationship with early resistance was analysed with logistic regressions. The rTB demonstrated to be the best predictor of early failure in both patient subsets, being superior to the multiparameter International Prognostic Score. The rTB showed a significant exponential relationship with the relative risk of early failure, and with inclusion of the extranodal involvement into the model, a single equation became adequate to predict resistance in both early unfavourable and advanced stage patients. The conclusions are that the rTB is the best pretreatment factor related to the risk of resistance to combined ABVD + radiotherapy and that this relationship can be mathematically expressed in an easy way. A simplified assessment of rTB is highly desirable.

AB - The purpose of the work was to investigate the factors predicting early resistance to treatment in Hodgkin lymphoma. Many staging parameters, including relative tumour burden (rTB), were analysed in 246 patients with Hodgkin lymphoma in relation to early failure, that is, less than complete remission (i.e. partial response, null response or progression) or occurrence of early relapse, as clinical expressions of resistance to treatment. Patients with early unfavourable disease were 129 and were treated with four to six cycles of ABVD + involved field radiotherapy; 117 patients with advanced stage disease received six cycles of ABVD + optional irradiation to no more than two sites. The rTB was volumetrically measured through the evaluation of staging computed tomography for all the lesions except bone marrow involvement, which was quantified by calculation. The relationship with early resistance was analysed with logistic regressions. The rTB demonstrated to be the best predictor of early failure in both patient subsets, being superior to the multiparameter International Prognostic Score. The rTB showed a significant exponential relationship with the relative risk of early failure, and with inclusion of the extranodal involvement into the model, a single equation became adequate to predict resistance in both early unfavourable and advanced stage patients. The conclusions are that the rTB is the best pretreatment factor related to the risk of resistance to combined ABVD + radiotherapy and that this relationship can be mathematically expressed in an easy way. A simplified assessment of rTB is highly desirable.

KW - Chemotherapy

KW - Clinical response

KW - Early relapse

KW - Radiotherapy

KW - Tumour burden

UR - http://www.scopus.com/inward/record.url?scp=84870942655&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870942655&partnerID=8YFLogxK

U2 - 10.1002/hon.1024

DO - 10.1002/hon.1024

M3 - Article

C2 - 22271092

AN - SCOPUS:84870942655

VL - 30

SP - 194

EP - 199

JO - Hematological Oncology

JF - Hematological Oncology

SN - 0278-0232

IS - 4

ER -